australian financial review today

Looks like there was an article in today's (or yesterday's) Australian Financial Review referencing Biota.

Here is an article from www.tradingmarkets.com that referenced the story:

Jan 05, 2011 (The Australian Financial Review - ABIX via COMTEX) -- Biota Holdings has a unique position among Australian-listed biotechnology stocks, in that it is gaining royalties from its second product while its first still has some years to run on its patents. The Relenza influenza treatment is being followed by a longer-lasting version called Inavir. Many other biotechs are working on their second product now, but are some years away from bringing these to market. Sector participants must strike the right balance between extending existing drugs' patent lifespans and investing in the development of new ones.
Publication Date: 6 January 2011